Aura Biosciences annual stock-based compensation
2020
2021
2022
2023
2024
2025
Aura Biosciences Stock-Based Compensation Growth & History (AURA)
Aura Biosciences's stock-based compensation was $14.3M for fiscal 2025.
View full Aura Biosciences company overviewAura Biosciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $14.3M | $2.6M | +22.14% |
| 2024 | 2024-12-31 | $11.7M | $3.0M | +33.63% |
| 2023 | 2023-12-31 | $8.8M | $2.4M | +36.81% |
| 2022 | 2022-12-31 | $6.4M | $4.1M | +177.94% |
| 2021 | 2021-12-31 | $2.3M | $1.6M | +213.45% |
| 2020 | 2020-12-31 | $736,000 | — | — |
Aura Biosciences quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.4M | $8.5M | +222.67% |
| Q1 2026 | 2026-03-31 | $3.8M | $310,000 | +8.82% |
| Q4 2025 | 2025-12-31 | $3.3M | $345,000 | +11.75% |
| Q3 2025 | 2025-09-30 | $3.7M | $938,000 | +34.11% |
| Q2 2025 | 2025-06-30 | $3.8M | $707,000 | +22.62% |
| Q1 2025 | 2025-03-31 | $3.5M | $605,000 | +20.80% |
| Q4 2024 | 2024-12-31 | $2.9M | $334,000 | +12.83% |
| Q3 2024 | 2024-09-30 | $2.8M | $425,000 | +18.28% |
| Q2 2024 | 2024-06-30 | $3.1M | $1.2M | +61.89% |
| Q1 2024 | 2024-03-31 | $2.9M | $996,000 | +52.06% |
| Q4 2023 | 2023-12-31 | $2.6M | $789,000 | +43.50% |
| Q3 2023 | 2023-09-30 | $2.3M | $608,000 | +35.41% |
| Q2 2023 | 2023-06-30 | $1.9M | $644,000 | +50.04% |
| Q1 2023 | 2023-03-31 | $1.9M | $319,000 | +20.01% |
| Q4 2022 | 2022-12-31 | $1.8M | $517,000 | +39.86% |
| Q3 2022 | 2022-09-30 | $1.7M | $1.2M | +209.93% |
| Q2 2022 | 2022-06-30 | $1.3M | $1.0M | +374.91% |
| Q1 2022 | 2022-03-31 | $1.6M | $1.4M | +761.62% |
| Q4 2021 | 2021-12-31 | $1.3M | — | — |
| Q3 2021 | 2021-09-30 | $554,000 | $363,000 | +190.05% |
| Q2 2021 | 2021-06-30 | $271,000 | — | — |
| Q1 2021 | 2021-03-31 | $185,000 | — | — |
| Q3 2020 | 2020-09-30 | $191,000 | — | — |
Aura Biosciences stock-based compensation trends
Over the last five fiscal years, Aura Biosciences's stock-based compensation increased from $736,000 to $14.3M, a change of $13.6M. The latest reported quarter, Q2 2026, shows $12.4M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aura Biosciences source filings ↗